Goldman Sachs’s BioCryst Pharmaceuticals BCRX Stock Holding History

Goldman Sachs’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-342,000	Closed	-$2.17M	–	6753
2016 Q4	$2.17M	Buy	+342,000	New	+$1.78M	﹤0.01%	3781
2016 Q1	–	Sell	-25,000	Closed	-$258K	–	7081
2015 Q4	$258K	Hold	25,000	–	–	﹤0.01%	5484
2015 Q3	$285K	Buy	+25,000	New	+$334K	﹤0.01%	5654
2014 Q4	–	Sell	-28,600	Closed	-$280K	–	7117
2014 Q3	$280K	Sell	28,600 -340,900	-92%	-$4.18M	﹤0.01%	5821
2014 Q2	$4.71M	Buy	+369,500	New	+$3.59M	﹤0.01%	3113

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Goldman Sachs's BCRX Position: Q1 2026 in Review

Goldman Sachs reduced its BioCryst Pharmaceuticals (BCRX) stake by 27% in Q1 2026, selling an estimated $6.72M and leaving 2,347,443 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

Goldman Sachs first reported a position in BCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $31.6M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Goldman Sachs held 2,347,443 shares of BioCryst Pharmaceuticals worth $22.3M as of Q1 2026.
Goldman Sachs sold 865,342 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $6.72M.
BioCryst Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2331 holding.
Goldman Sachs first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's BioCryst Pharmaceuticals position peaked at $31.6M in Q2 2025.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.